Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors

Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors: A Prospective, Single-Arm Clinical Study

Evaluation of Sup19 CAR-T cells in cases where previous CD19-targeted therapy has failed or where CD19 Evaluation of Safety and Efficacy in the Treatment of Low-Grade Hematological Malignancies: A Prospective, Single-Arm Clinical Study Research

Study Overview

• Status: Not yet recruiting
• Conditions: B-Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia/Lymphoma
• Intervention / Treatment: Biological: Sup19 CAR-T

• Study Type: Interventional
• Enrollment (Estimated): 9
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: wangying PI; Phone Number: 15900225626; Email: wangying1@ihcams.ac.cn

Study Locations

• China
  • Tianjin Municipality
    • Tianjin, Tianjin Municipality, China, 300000
      • Institute of Hematology, Chinese Academy of Medical Sciences & Hospital of Hematology, Chinese Academy of Medical Sciences

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients aged ≥18 and <70 years, of any gender;
• diagnosed with B-ALL/LBL according to the criteria of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Lymphoblastic Leukemia (2020.v1) and B-cell Lymphoma Clinical Practice Guidelines (2020.v1);
• meeting either of the following two criteria: (1) Previous targeted CD19 therapy, including bispecific antibodies, ADC drugs, and CAR-T, with continued CD19 expression; (2) Patients with hematological malignancies who have not received CD19-targeted therapy in the past, with weakly positive CD19 expression;
• At the time of screening, the number of blasts in the bone marrow is 25% (bone marrow morphology) and/or extramedullary lesions;
• Meeting the diagnosis of relapsed/refractory B-ALL/LBL, including any of the following situations: a. Primary refractory patients who have not achieved complete remission after two cycles of standardized chemotherapy or patients who have not achieved complete remission after multiple salvage chemotherapy regimens; b. Patients who relapse within 12 months after achieving complete remission or relapse after 12 months of achieving complete remission and have not achieved complete remission after one or more courses of standard treatment induction; c. Patients who relapse after hematopoietic stem cell transplantation or after CAR-T therapy targeting the same target;
• Other relapsed/refractory CD19 weakly expressing hematological malignancies;
• Creatinine clearance rate > 60 ml/min (Cockcroft and Gault formula); for patients without liver involvement, total serum bilirubin < 3 times the upper limit of normal, and both serum ALT and AST < 5 times the upper limit of the normal range.
• Echocardiography shows left ventricular ejection fraction (LVEF) of 250%;
• Finger pulse oxygen saturation > 92%;--Estimated survival period of more than 3 months;
• Estimated survival period of more than 3 months;
• ECOG score of 0-2;
• The subject or his/her legal guardian voluntarily participates in this trial and signs the informed consent form.

Exclusion Criteria:

• Acute promyelocytic leukemia (APL);
• presence of hereditary syndromes such as Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or any other known myelodysplastic syndrome;
• uncontrolled active central nervous system leukemia (CNSL), i.e., cerebrospinal fluid (CSF) classification CNS 3;
• prior administration of antineoplastic therapy before infusion; exclusion criteria include: a. Received systemic chemotherapy within 1 week (excluding pre-treatment); b. Those who have received monoclonal antibody treatment, with the time from the last monoclonal antibody infusion to the screening being less than 5 half-lives or 4 weeks (whichever is shorter); c. Received donor lymphocyte infusion (DLI) within 6 weeks;
• Had uncontrolled severe active infection at screening;
• Had a history of severe heart disease, including: severe heart dysfunction (according to the New York Heart Association (NYHA) cardiac function classification criteria, subjects with grade III or V cardiac dysfunction), myocardial infarction within 12 months or undergoing coronary angioplasty or stent placement, unstable angina pectoris, or electrocardiogram indicating a significantly prolonged QT interval (>480ms) or the investigator determined severe arrhythmia;
• Had a history of head trauma, consciousness disorder, epilepsy, cerebrovascular ischemia, or cerebrovascular hemorrhagic disease, and required medication within the past 6 months;
• Had hepatitis B surface antigen (HBsAg) greater than 10E6 IU/mL at screening; positive hepatitis C virus (HCV) antibody; positive human immunodeficiency virus (HIV) antibody; positive syphilis antibody; EBER positive or EBV copy number > upper limit of normal;
• Those who require the use of steroid hormones during CAR-T infusion (except for those using inhaled steroid hormones locally); subjects who are receiving systemic steroid treatment before screening and whose study investigators determine that they need long-term systemic steroid treatment during the treatment period (excluding those using inhaled or local steroid hormones);
• Subjects with treatable autoimmune diseases, immunodeficiency or those requiring immunosuppressive therapy;
• Subjects who had acute graft-versus-host disease (GvHD) or moderate to severe chronic GvHD within 4 weeks before screening;
• Subjects with a history of allergy to any component of the cell product;
• Pregnant or lactating women, as well as male or female subjects who have reproductive capacity and cannot take effective contraceptive measures within 1 year after cell infusion (regardless of gender); male subjects who plan to conceive within 1 year after cell infusion; female subjects or their partners who plan to conceive within 1 year after cell infusion;
• Any situation that the investigator considers may increase the risk for the subject or interfere with the test results.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 3 dose groups; Using a dose escalation and rapid titration design, the CAR-T dose groups were (1) 0.5×10^6 CAR-T cells/kg; (2) 1×10^6 CAR-T cells/kg; (3) 3×10^6 CAR-T cells/kg.	Biological: Sup19 CAR-T; The use of Sup19 CAR-T cells to treat hematologic malignancies with prior CD19-targeted therapy failure or CD19 weak expression aims to improve the relapse-free survival rate in patients with hematologic malignancies, providing a novel curative strategy for these patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety evaluation of Sup19 CAR-T cell therapy in patients with hematologic malignancies who have failed prior CD19-targeted therapy or exhibit weak CD19 expression: dose-limiting toxicity (DLT) adverse events (with particular focus on CRS and ICANS)	up to 28 after CAR-T cell infusion

Secondary Outcome Measures

Outcome Measure	Time Frame
The best response rate of Sup19 CAR-T cell therapy within 3 months(The proportion of patients achieving CR/CRi)	Sup19 CAR-T cell therapy within 3 months
Duration of response (DOR)	After the Sup19 CAR-T infusion, the time from the first achievement of CR/CRi + PR to disease recurrence or death due to leukemia (follow-up monitoring until 3 years after infusion).
Event-free Survival, (EFS）	The time from the administration of Sup19 CAR-T to the earliest occurrence of the event (follow-up monitoring until 3 years after infusion)
Leukemia-free Survival, (LFS）	The time from the first occurrence of CR/CRi (ALL/LBL) to recurrence or death. (follow-up monitoring until 3 years after infusion)
The proportion of patients who received hematopoietic stem cell transplantation under the alleviated condition	The proportion of subjects who achieved remission after infusion and who received HSCT. (Follow-up monitoring was conducted until 3 years after the infusion)
Overall Survival,(OS）	The time from the first infusion of CAR-T cells to death due to any cause (Follow-up monitoring was conducted until 3 years after the infusion)
Negative rate of Minimal Residual Disease（MRD）	28 days after the Sup19 CAR-T infusion

Collaborators and Investigators

• Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): November 1, 2027
• Study Completion (Estimated): November 1, 2027

Study Registration Dates

• First Submitted: January 15, 2026
• First Submitted That Met QC Criteria: April 13, 2026
• First Posted (Actual): April 20, 2026

Study Record Updates

• Last Update Posted (Actual): April 20, 2026
• Last Update Submitted That Met QC Criteria: April 13, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Infections; Virus Diseases; Neoplasms by Histologic Type; DNA Virus Infections; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma, B-Cell; Epstein-Barr Virus Infections; Herpesviridae Infections; Tumor Virus Infections; Hemic and Lymphatic Diseases; Lymphoma; Burkitt Lymphoma
• Other Study ID Numbers: IIT2025126

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No